MX2017002453A - Neprilisina como marcador pronostico de insuficiencia cardiaca. - Google Patents
Neprilisina como marcador pronostico de insuficiencia cardiaca.Info
- Publication number
- MX2017002453A MX2017002453A MX2017002453A MX2017002453A MX2017002453A MX 2017002453 A MX2017002453 A MX 2017002453A MX 2017002453 A MX2017002453 A MX 2017002453A MX 2017002453 A MX2017002453 A MX 2017002453A MX 2017002453 A MX2017002453 A MX 2017002453A
- Authority
- MX
- Mexico
- Prior art keywords
- heart failure
- neprilysin
- prognostic marker
- failure prognostic
- determining
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
- G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
- G01N2333/96497—Enkephalinase (3.4.24.11)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14182846.7A EP2990800A1 (en) | 2014-08-29 | 2014-08-29 | Neprilysin as heartfailure (HF) prognostic marker |
| PCT/EP2015/068729 WO2016030209A1 (en) | 2014-08-29 | 2015-08-14 | Neprilysin as heart failure prognostic marker |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017002453A true MX2017002453A (es) | 2017-10-23 |
Family
ID=51421966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017002453A MX2017002453A (es) | 2014-08-29 | 2015-08-14 | Neprilisina como marcador pronostico de insuficiencia cardiaca. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10203341B2 (enExample) |
| EP (2) | EP2990800A1 (enExample) |
| JP (1) | JP6661216B2 (enExample) |
| CN (1) | CN107076758B (enExample) |
| AU (1) | AU2015309112A1 (enExample) |
| CA (1) | CA2959094A1 (enExample) |
| ES (1) | ES2734876T3 (enExample) |
| MX (1) | MX2017002453A (enExample) |
| RU (1) | RU2017109086A (enExample) |
| SG (1) | SG11201701393YA (enExample) |
| WO (1) | WO2016030209A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12699104B2 (en) | 2019-11-06 | 2026-08-04 | National University Corporation Kagawa University | Heart failure marker |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003020762A1 (en) * | 2001-09-03 | 2003-03-13 | Intreat Pty Limited | Antibodies to non-functional p2x7receptor, diagnosis and treatment of cancers and other conditions |
| MX340078B (es) * | 2009-11-07 | 2016-06-24 | Astute Medical Inc | Metodos y composiciones para el diagnostico y pronostico de daño renal y falla renal. |
| EP2360280A1 (en) * | 2010-02-24 | 2011-08-24 | Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol | Genetic marker for the diagnosis of dementia with Lewy bodies |
| JP2014505259A (ja) * | 2011-02-03 | 2014-02-27 | アボット・ラボラトリーズ | 慢性心不全における予後診断および診断の方法 |
| IN2014MN02101A (enExample) * | 2012-04-12 | 2015-08-28 | Brahms Gmbh | |
| RU2667643C2 (ru) * | 2012-08-24 | 2018-09-21 | Новартис Аг | Ингибиторы nep для лечения заболеваний, характеризующихся увеличением или ремоделированием предсердия |
| US20140206632A1 (en) | 2013-01-22 | 2014-07-24 | Singulex, Inc. | Endothelin in the Diagnosis of Cardiac Disease |
| WO2014126972A1 (en) * | 2013-02-14 | 2014-08-21 | Novartis Ag | Substituted bisphenyl butanoic acid derivatives as nep inhibitors with improved in vivo efficacy |
| SG11201506018PA (en) * | 2013-02-14 | 2015-08-28 | Novartis Ag | Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors |
-
2014
- 2014-08-29 EP EP14182846.7A patent/EP2990800A1/en not_active Withdrawn
-
2015
- 2015-08-14 RU RU2017109086A patent/RU2017109086A/ru not_active Application Discontinuation
- 2015-08-14 AU AU2015309112A patent/AU2015309112A1/en not_active Abandoned
- 2015-08-14 ES ES15750737T patent/ES2734876T3/es active Active
- 2015-08-14 CA CA2959094A patent/CA2959094A1/en not_active Abandoned
- 2015-08-14 WO PCT/EP2015/068729 patent/WO2016030209A1/en not_active Ceased
- 2015-08-14 US US15/506,665 patent/US10203341B2/en not_active Expired - Fee Related
- 2015-08-14 MX MX2017002453A patent/MX2017002453A/es unknown
- 2015-08-14 EP EP15750737.7A patent/EP3186639B1/en not_active Not-in-force
- 2015-08-14 SG SG11201701393YA patent/SG11201701393YA/en unknown
- 2015-08-14 JP JP2017511945A patent/JP6661216B2/ja not_active Expired - Fee Related
- 2015-08-14 CN CN201580050585.0A patent/CN107076758B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2959094A1 (en) | 2016-03-03 |
| EP3186639A1 (en) | 2017-07-05 |
| US10203341B2 (en) | 2019-02-12 |
| CN107076758A (zh) | 2017-08-18 |
| SG11201701393YA (en) | 2017-03-30 |
| JP2017526924A (ja) | 2017-09-14 |
| WO2016030209A1 (en) | 2016-03-03 |
| AU2015309112A1 (en) | 2017-04-06 |
| ES2734876T3 (es) | 2019-12-12 |
| CN107076758B (zh) | 2019-10-22 |
| US20170254815A1 (en) | 2017-09-07 |
| EP3186639B1 (en) | 2019-03-20 |
| EP2990800A1 (en) | 2016-03-02 |
| RU2017109086A (ru) | 2018-10-01 |
| JP6661216B2 (ja) | 2020-03-11 |
| RU2017109086A3 (enExample) | 2019-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3757225A3 (en) | Pancreatic cancer detection kit or device, and detection method | |
| EP4060048A3 (en) | Non-invasive diagnostic method for diagnosing bladder cancer | |
| EP4464797A3 (en) | Kit, device, and method for detecting lung cancer | |
| EP3816303A3 (en) | Breast cancer detection kit or device, and method for detecting breast cancer | |
| EA201590027A1 (ru) | Способы детекции заболеваний или состояний | |
| EP3967769A3 (en) | Lung cancer detection kit or device, and detection method | |
| WO2014201516A3 (en) | Biomarker identification | |
| BR112018069849A2 (pt) | kit, dispositivo e método para a detecção de câncer pancreático precoce ou de lesão precursora do câncer pancreático | |
| BR112012030587A2 (pt) | métodos para diagnóstico de câncer pancreático, para identificar se um indivíduo precisa ou não de uma terapia contra câncer pancreático e para determinar se uma terapia contra câncer pancreático obtém sucesso, dispositivo para diagnóstico de câncer pancreático e uso de pelo menos um biomarcador | |
| MX2016012285A (es) | Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf. | |
| WO2016063068A3 (en) | Method and apparatus for the analysis of compounds | |
| EP4202441A3 (en) | Gene expression profile in macrophages for the diagnosis of cancer | |
| EA201790769A1 (ru) | Определение уровней гликозаминогликанов методом масс-спектрометрии | |
| MX2017003370A (es) | Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica. | |
| BR112016016101A2 (pt) | Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos | |
| BR112018008799A2 (pt) | método de prognóstico | |
| WO2015077382A3 (en) | Combined cytology and molecular testing for early detection of esophageal adenocarcinoma | |
| MX2019002818A (es) | Metodos para detectar anticuerpos neutralizantes anti-leptina. | |
| EP4428251A3 (en) | Methods of detecting prostate cancer | |
| GB2552271A (en) | A method for diagnosing lung cancer | |
| EP3206032A4 (en) | Method for detecting cardiac failure patient, method for discrimination of cardiac disease, test reagent for cardiac failure, test kit for cardiac failure, device for detecting cardiac failure, and program for detecting cardiac failure | |
| WO2016012864A3 (en) | Biomarkers for anderson-fabry disease | |
| MX347311B (es) | Métodos y circuitos para medir un elemento de impedancia alta con base en las mediciones de constantes de tiempo. | |
| MX2015015015A (es) | Metodo para diagnosticar cancer. | |
| MX384636B (es) | Método para detectar anticuerpos neutralizantes contra la insulina humana recombinante en suero humano. |